Trials Sponsors Conditions Drugs Pricing

Conditions

Glioblastoma Multiforme Healthy Volunteers

Keywords

GBMBrain TumorBrain NeoplasmControlNormal ControlVolunteer

Outcome Measures

Primary Outcomes (1)

Identification of Human GBM CD Antigen Signature.
Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.
3 Years

Secondary Outcomes (3)

Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.
3 Years
Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.
3 Years
Prospective Evaluation of the Routine Medical History of GBM Patients.
3 Years

Study Arms (2)

GBM Patients

GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.

Other: GBM Patients

Normal Controls

Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.

Other: Normal Controls

Interventions

GBM PatientsOther

2 teaspoons of blood will be collected during select clinic visits.

GBM Patients

Normal ControlsOther

2 teaspoons of blood will be collected once.

Normal Controls

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 89 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Participants will be recruited during routine interactions with the investigators.

You may qualify if:

to 89 years of age

Sponsors & Collaborators

University of Florida
Otherlead

Study Sites (1)

University of Florida

Gainesville, Florida, 32610, United States

MeSH Terms

Conditions

GlioblastomaBrain Neoplasms

Condition Hierarchy (Ancestors)

AstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteBrain Diseases

Study Officials

Brent Reynolds, PhD
University of Florida
PRINCIPAL INVESTIGATOR

Enrollment

130 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 24, 2010

First Posted

June 3, 2010

Study Start

October 2009

Date type not reported

This date has not been verified as actual or estimated.

Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

GBM Patients

Normal Controls

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

GBM Patients

Normal Controls

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations